AI Article Synopsis
- Triple therapy is commonly used to treat Helicobacter pylori infections, but issues like poor compliance and antibiotic resistance can lead to treatment failures.
- A study involving 48 H. pylori-positive patients assessed the effectiveness of a rifaximin-based triple therapy, comparing two different antibiotic regimens for H. pylori eradication.
- Results showed that rifaximin had good patient compliance but lower eradication rates (58% vs. 42%) when compared to standard treatments; further research is necessary to explore better dosing and combinations.
Article Abstract
Background: Triple therapy is the treatment of choice for Helicobacter pylori-infected patients with an eradication rate ranging from 70 to 85%. Poor compliance and antibiotic resistance are the main causes of treatment failure. The aim of the present study was to assess the efficacy of rifaximin, a poorly absorbed antibiotic, for H. pylori eradication.
Methods: We enrolled 48 consecutive H. pylori-positive patients affected. They were randomized to receive two 7-day rifaximin-based triple therapies: rifaximin tablets 400 mg t.i.d., esomeprazole 40 mg o.d. and clarithromycin 500 mg b.i.d. (CRE) or levofloxacin 500 mg o.d. (LRE). H. pylori eradication was assessed using a (13)C-urea breath test 4 weeks after the end of therapy. Treatment compliance and the incidence of side effects were also evaluated.
Results: No dropouts were observed. The eradication rate both on intention-to-treat and per-protocol analysis did not show significant differences between groups: 58% (14/24 patients) in group 1 and 42% (10/24 patients) in group 2 (p = 0.24, OR 1.96, 95% CI 0.62-6.18). No significant differences in patients' compliance and incidence of side effects were found between groups.
Conclusions: Rifaximin-based therapy showed optimal compliance but a limited eradication rate compared to standard first-line treatment. Further investigations are needed to evaluate different dosages and combinations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000090330 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate using a co-spheroid 3D model of pancreatic cancer.
J Gastroenterol
January 2025
Division of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham (UAB), Birmingham, Alabama, 35294, USA.
Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a high mortality rate and exhibits a limited response to apoptosis-dependent chemotherapeutic drugs (e.g., gemcitabine, Gem).
View Article and Find Full Text PDFHouse dust mites eradication treatments: Current updates emphasizing on tropical countries.
Trop Biomed
December 2024
Division of Biomedical Sciences, School of Pharmacy, University of Nottingham Malaysia, 43500, Semenyih, Malaysia.
House Dust Mites (HDMs) like Dermatophagoides farinae (D. farinae), Dermatophagoides pteronyssinus (D. pteronyssinus) and Blomia tropicalis (B.
View Article and Find Full Text PDFMolecular characteristics of avian leukosis viruses isolated from indigenous chicken breeds in Yunnan Province, Southwestern China.
Poult Sci
January 2025
College of Veterinary Medicine, Yunnan Agricultural University, Kunming 650201, PR China; Center for Poultry Disease Control and Prevention, Yunnan Agricultural University, Kunming 650201, PR China. Electronic address:
Indigenous chicken breeds have a large market share in China due to their superior production traits, including high meat quality and disease resistance. Yunnan Province is recognized as a major source of domestic chickens globally and boasts a diverse array of indigenous chicken resources. Avian leukosis virus (ALV) induces various tumors and immunosuppression, endangering the poultry industry.
View Article and Find Full Text PDFIntroduction: Lotilaner ophthalmic solution (0.25%) is the first United States Food and Drug Administration (US FDA)-approved drug for treating Demodex blepharitis. In pivotal trials, it was found to be well tolerated and demonstrated a significant reduction in collarettes and mite density after a 6-week treatment regimen.
View Article and Find Full Text PDFLong-term outcomes after endoscopic eradication therapy for dysplastic and T1a adenocarcinoma related Barrett's esophagus: higher rate of late dysplastic recurrence with radio-frequency ablation monotherapy.
Gastrointest Endosc
January 2025
Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia; University of Melbourne, Melbourne, Australia. Electronic address:
Background & Aims: There is conflicting literature describing the durability of complete remission of intestinal metaplasia (CRIM) after endoscopic eradication therapy (EET) for Barrett's esophagus (BE). We aim to assess the timeline, predictors and long-term outcomes of recurrence.
Methods: Data on 365 patients who underwent EET for dysplastic BE were collected prospectively between 2008 and 2022 at a Barrett's referral unit.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!